Autor: |
Enrique O Graue-Hernandez, Sergio Hernandez-Jimenez, David Kershenobich-Stalnikowitz, Ana Cristina García-Ulloa, Carlos Alberto Aguilar-Salinas, Denise Arcila-Martínez, Rodrigo Arizmendi-Rodríguez, Humberto Del Valle-Ramírez, Fernanda Garnica-Carrillo, Eduardo González-Flores, Mariana Granados-Arcos, Héctor Infanzón-Talango, Claudia Lechuga-Fonseca, Liliana Pérez-Peralta, David Rivera de la Parra, Sofía Ríos-Villavicencio, Francis Rojas-Torres, Sandra Sainos-Muñoz, Alejandra Sierra-Esquivel, Luz Elena Urbina-Arronte, María Luisa Velasco-Pérez, Héctor Velázquez-Jurado, Andrea Villegas-Narváez, Verónica Zurita-Cortés, María Teresa Alcántara-Garcés, Michelle Díaz-Pineda, Arturo Flores García, María Victoria Landa-Anell, Marco Antonio Melgarejo-Hernández, Pablo Anaya, Ricardo Gasca-Pineda, Luis Arturo Sánchez-Trujillo, Héctor Peña Baca, Eduardo González-Pier, Franciso Javier Gómez-Pérez, Angélica Palacios-Vargas, Diana Hernández-Juárez, Arely Hernández-Jasso |
Jazyk: |
angličtina |
Rok vydání: |
2021 |
Předmět: |
|
Zdroj: |
BMJ Open Diabetes Research & Care, Vol 9, Iss 1 (2021) |
Druh dokumentu: |
article |
ISSN: |
2052-4897 |
DOI: |
10.1136/bmjdrc-2020-002097 |
Popis: |
Introduction To assess the cost-effectiveness of a multidisciplinary and comprehensive innovative diabetes care program (CAIPaDi) versus usual treatment in public health institutions.Research design and methods Using a cost-effectiveness analysis, we compared the CAIPaDi program versus usual treatment given in Mexican public health institutions. The analysis was based on the IQVIA Core Diabetes Model, a validated simulation model used to estimate long-term clinical outcomes. Data were prospectively obtained from the CAIPaDi program and from public databases and published papers. Health outcomes were expressed in terms of life-years gained and quality-adjusted life years (QALYs). Health and economic outcomes were estimated from a public perspective and discounted at 5% per year over a 20-year horizon. Costs are reported in US dollars (US$) of 2019. A probabilistic sensitivity analysis was performed using life-years gained and QALYs.Results The CAIPaDi costs on average US$559 (95% CI: −$879 to −$239) less than the usual treatment (95% CI: −$879 to −$239) and produced a difference in mean life-years gained (0.48, 95% CI: 0.45 to 0.52) and mean QALYs (1.43, 95% CI: 1.40 to 1.46). The cost-effectiveness ratio resulted in a saving per life-year gained of −US$1155 (95% CI: −$1962 to −$460). Mean differences in QALYs resulted in a saving per QALY of −US$735 (95% CI: −$1193 to −$305). Probabilistic sensitivity analysis proved the results are robust on both life-years gained and QALYs.Conclusions CAIPaDi has a better cost-effectiveness ratio than the usual therapy in Mexican public health institutions. |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|